全文获取类型
收费全文 | 1296篇 |
免费 | 87篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 56篇 |
妇产科学 | 6篇 |
基础医学 | 123篇 |
口腔科学 | 21篇 |
临床医学 | 109篇 |
内科学 | 313篇 |
皮肤病学 | 44篇 |
神经病学 | 114篇 |
特种医学 | 63篇 |
外国民族医学 | 10篇 |
外科学 | 237篇 |
综合类 | 8篇 |
预防医学 | 146篇 |
眼科学 | 9篇 |
药学 | 65篇 |
肿瘤学 | 56篇 |
出版年
2023年 | 10篇 |
2022年 | 17篇 |
2021年 | 37篇 |
2020年 | 26篇 |
2019年 | 51篇 |
2018年 | 70篇 |
2017年 | 30篇 |
2016年 | 34篇 |
2015年 | 34篇 |
2014年 | 42篇 |
2013年 | 75篇 |
2012年 | 99篇 |
2011年 | 106篇 |
2010年 | 49篇 |
2009年 | 61篇 |
2008年 | 75篇 |
2007年 | 65篇 |
2006年 | 80篇 |
2005年 | 62篇 |
2004年 | 52篇 |
2003年 | 48篇 |
2002年 | 48篇 |
2001年 | 15篇 |
2000年 | 12篇 |
1999年 | 19篇 |
1998年 | 7篇 |
1997年 | 5篇 |
1996年 | 8篇 |
1995年 | 4篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 15篇 |
1991年 | 11篇 |
1990年 | 16篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 12篇 |
1984年 | 3篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1974年 | 5篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1970年 | 7篇 |
1969年 | 2篇 |
排序方式: 共有1385条查询结果,搜索用时 15 毫秒
21.
22.
Knobel H Escobar I Polo R Ortega L Martín-Conde MT Casado JL Codina C Fernández J Galindo MJ Ibarra O Llinas M Miralles C Riera M Fumaz CR Segador A Segura F Chamorro L 《Enfermedades infecciosas y microbiología clínica》2005,23(4):221-231
Since the early days of antiretroviral therapy, adherence has emerged as the milestone of success; in fact, it is the most potent predictor of effectiveness. The main factors related to adherence include the complexity of the therapeutic regimen, adverse effects, psychological problems, alcoholism and active addiction to drugs, lack of social and family support and the patient's beliefs and attitudes about the treatment. Adherence monitoring should be part of the HIV patient's regular care, and should be done with feasible, easily applied methods adapted to the different clinical settings. The minimally acceptable measures should include use of a validated questionnaire, together with data from the Pharmacy Department's drug dispensation registry. All patients that begin HAART or undergo a change of treatment should participate in a treatment education program imparted by health professionals with knowledge and experience in the management of patients with HIV infection. The health team (doctors, pharmacists and nursing professionals) should offer maximum availability to solve the doubts and problems that may occur during treatment. When sub-optimal adherence is detected, intervention strategies based on psychological therapy, educational efforts and personal advice should be attempted, in order to adapt the treatment scheme to the patient's habits and provide solutions to the problem of non-compliance. In certain situations, co-morbid conditions will also require attention. Treatment adherence, being a multidimensional problem, needs a multidisciplinary team approach. The choice of therapy, only one aspect of the multidimensional problem of adherence, must be a careful and individualized decision; however, simpler regimens with regard to the number of pills and daily dose are desirable. 相似文献
23.
24.
25.
Laia Garcia-Bellmunt Oriol Sibila Ingrid Solanes Ferran Sanchez-Reus Vicente Plaza 《Archivos de bronconeumología》2012
Introduction
Pulmonary nocardiosis (PN) is a severe infection with a high morbidity and mortality that mainly affects immunocompromised patients. In recent years, an increase in PN cases has been detected among patients with chronic obstructive pulmonary disease (COPD). The factors that are associated with its presence and determine its prognosis remain unknown.Methods
Retrospective study of COPD patients diagnosed with PN over the period from 1997-2009 at the Hospital de la Santa Creu i Sant Pau, in Barcelona (Spain). Demographic, clinical, microbiological and evolution data were evaluated in all casesResults
Thirty patients were identified with PN and COPD. Mean age (standard deviation) was 76 (7) years and the mean FEV1 was 40 (14)%. Chronic respiratory failure was observed in 56,7% patients and 51,7% had received systemic corticosteroid therapy previous to the PN diagnosis. The most common symptoms were cough and dyspnea (90%). Alveolar infiltrates were observed in 60% of the cases. The most frequently isolated Nocardia species was N. cyriacigeorgica (68%). The one-month mortality rate was 17%, while the one-year mortality rate was 33%. The factors associated with mortality within the first year included previous systemic corticosteroid treatment, less than three months of specific antibiotic therapy and active associated neoplasm.Conclusions
PN affects patients with moderate-severe COPD and has high short- and mid-term mortality rates. Previous corticosteroid treatment, specific antibiotic therapy for less than 3 months and active neoplasia were factors associated with mortality. 相似文献26.
27.
28.
29.
30.
Francisco Maduell Francesc Moreso Mercedes Pons Rosa Ramos Josep Mora-Macià Jordi Carreras Jordi Soler Ferran Torres Josep M. Campistol Alberto Martinez-Castelao for the ESHOL Study Group 《Journal of the American Society of Nephrology : JASN》2013,24(3):487-497
Retrospective studies suggest that online hemodiafiltration (OL-HDF) may reduce the risk of mortality compared with standard hemodialysis in patients with ESRD. We conducted a multicenter, open-label, randomized controlled trial in which we assigned 906 chronic hemodialysis patients either to continue hemodialysis (n=450) or to switch to high-efficiency postdilution OL-HDF (n=456). The primary outcome was all-cause mortality, and secondary outcomes included cardiovascular mortality, all-cause hospitalization, treatment tolerability, and laboratory data. Compared with patients who continued on hemodialysis, those assigned to OL-HDF had a 30% lower risk of all-cause mortality (hazard ratio [HR], 0.70; 95% confidence interval [95% CI], 0.53–0.92; P=0.01), a 33% lower risk of cardiovascular mortality (HR, 0.67; 95% CI, 0.44–1.02; P=0.06), and a 55% lower risk of infection-related mortality (HR, 0.45; 95% CI, 0.21–0.96; P=0.03). The estimated number needed to treat suggested that switching eight patients from hemodialysis to OL-HDF may prevent one annual death. The incidence rates of dialysis sessions complicated by hypotension and of all-cause hospitalization were lower in patients assigned to OL-HDF. In conclusion, high-efficiency postdilution OL-HDF reduces all-cause mortality compared with conventional hemodialysis.In the last decades, renal replacement therapy with hemodialysis has become a standard of care for patients with ESRD. Despite continuous improvement, annual mortality among these patients ranges between 15% and 25%.1,2 Hemodialysis techniques are based on the ability of molecules to diffuse across a semipermeable membrane, which allows adequate clearance of low molecular weight particles. To increase the clearance of middle-to-large molecules, synthetic membranes with high water permeability (high-flux membranes) were introduced years ago. The anticipated benefit of high-flux over low-flux hemodialysis on patient survival was not confirmed in the Hemodialysis (HEMO) study.3 However, the Membrane Permeability Outcome (MPO) study,4 as well as a post hoc analysis in diabetic patients, showed that high-flux hemodialysis improved long-term survival in patients with hypoalbuminemia.Clearance of middle-to-large molecules can be increased by combining diffusive and convective transport through hemodiafiltration. The introduction of online hemodiafiltration (OL-HDF) using ultrapure dialysate as the source of the replacement fluid has allowed the convective volume to be increased and has reduced the cost of the procedure.5 Randomized studies with limited sample sizes and nonrandomized studies have shown that OL-HDF improves hemodynamic stability and response to erythropoietic-stimulating agents (ESAs) and reduces the incidence of hemodialysis-associated amyloidosis and chronic inflammation.6–11 The effect of OL-HDF on patient survival is derived from noncontrolled studies. The European Dialysis Outcomes and Practice Pattern Study was associated with a mortality risk reduction of 35% in patients treated with high-efficiency hemodiafiltration compared with those treated with conventional hemodialysis.12 These results were confirmed in other noncontrolled studies conducted in several European countries,13–15 although two recent, randomized studies failed to show differences in patient survival16,17In 2007, the Catalonian Health Authorities approved a specific additional reimbursement for OL-HDF to dialysis care providers and the Catalonian Society of Nephrology promoted this randomized study (On-Line Hemodiafiltration Survival Study, or Estudio de Supervivencia de Hemodiafiltración On-Line [ESHOL]) to compare the effect of OL-HDF over hemodialysis on patient survival.18 相似文献